14 November 2022 - The MAA was submitted in the EU for toripalimab seeking indications for the first-line treatment of NPC and the first-line treatment of ESCC.
Shanghai Junshi Biosciences announced today that the company has submitted a marketing authorisation application to the European Medicines Agency for toripalimab.